Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

Rafael R.G. Machado; Jordyn L. Walker; Dionna Scharton; Grace H. Rafael; Brooke M. Mitchell; Rachel A. Reyna; William M. de Souza; Jianying Liu; David H. Walker; Jessica A. Plante; Kenneth S. Plante; Scott C. Weaver

doi:10.1038/s41467-023-40033-2

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

Rafael R.G. Machado
, Jordyn L. Walker
, Dionna Scharton
, Grace H. Rafael
, Brooke M. Mitchell
, Rachel A. Reyna
, William M. de Souza
, Jianying Liu
, David H. Walker
, Jessica A. Plante
, Kenneth S. Plante
, Scott C. Weaver

Microbiology, Immunology, and Molecular Genetics

Producción científica: Article › revisión exhaustiva

8 Citas (Scopus)

Resumen

The SARS-CoV-2 Omicron subvariant BA.5 rapidly spread worldwide and replaced BA.1/BA.2 in many countries, becoming globally dominant. BA.5 has unique amino acid substitutions in the spike protein that both mediate immune escape from neutralizing antibodies produced by immunizations and increase ACE2 receptor binding affinity. In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). Notably, one high or low dose of Ad26.COV2.S provides more durable immunity than two primary doses of BNT162b2, and the NVX-CoV2373 booster provides the strongest augmentation of immunity, reduction in BA.5 viral replication, and disease. Our data demonstrate the immunogenicity and efficacy of different prime/boost vaccine regimens against BA.5 infection in an immune-competent model and provide new insights regarding COVID-19 vaccine strategies.

Idioma original	English
Número de artículo	4260
Publicación	Nature Communications
Volumen	14
N.º	1
DOI	https://doi.org/10.1038/s41467-023-40033-2
Estado	Published - dic 2023

Nota bibliográfica

Publisher Copyright:
© 2023, The Author(s).

Financiación

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 and grant R24 AI120942 (to S.C.W.), and by the Sealy and Smith Foundation (to SCW). During part of the study R.R.G.M. received a grant from Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP (2019/27803-2), W.M.S. is supported by a Global Virus Network fellowship. We thank the in vivo NIH-SAVE group for their thoughtful insights during the study, Nehad Saada, Allan McConnell and Patricia A. Valdes for technical assistance. We acknowledge the Anatomic Pathology Laboratory at University of Texas Medical Branch for tissue sectioning. The authors acknowledge Mimi Guebre-Xabier, Nita Patel, Gale Smith, and Greg Glenn at Novavax, Inc. for providing NVX-CoV2373 vaccine and Sayda M. Elbashir and Darin Edwards at Moderna, Inc. for providing the preclinical version of mRNA-1273 vaccine. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 and grant R24 AI120942 (to S.C.W.), and by the Sealy and Smith Foundation (to SCW). During part of the study R.R.G.M. received a grant from Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP (2019/27803-2), W.M.S. is supported by a Global Virus Network fellowship. We thank the in vivo NIH-SAVE group for their thoughtful insights during the study, Nehad Saada, Allan McConnell and Patricia A. Valdes for technical assistance. We acknowledge the Anatomic Pathology Laboratory at University of Texas Medical Branch for tissue sectioning. The authors acknowledge Mimi Guebre-Xabier, Nita Patel, Gale Smith, and Greg Glenn at Novavax, Inc. for providing NVX-CoV2373 vaccine and Sayda M. Elbashir and Darin Edwards at Moderna, Inc. for providing the preclinical version of mRNA-1273 vaccine.

Financiadores	Número del financiador
NIH-SAVE
National Institutes of Health (NIH)
U.S. Department of Health and Human Services	75N93021C00016, R24 AI120942
National Institute of Allergy and Infectious Diseases
Sealy and Smith Foundation
Fundação de Amparo à Pesquisa do Estado de São Paulo	2019/27803-2

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Acceder al documento

10.1038/s41467-023-40033-2

Otros archivos y enlaces

Citar esto

Machado, R. R. G., Walker, J. L., Scharton, D., Rafael, G. H., Mitchell, B. M., Reyna, R. A., de Souza, W. M., Liu, J., Walker, D. H., Plante, J. A., Plante, K. S., & Weaver, S. C. (2023). Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters. Nature Communications, 14(1), Artículo 4260. https://doi.org/10.1038/s41467-023-40033-2

@article{0f3965d5794d4ed58dedc35de93f46a3,

title = "Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters",

abstract = "The SARS-CoV-2 Omicron subvariant BA.5 rapidly spread worldwide and replaced BA.1/BA.2 in many countries, becoming globally dominant. BA.5 has unique amino acid substitutions in the spike protein that both mediate immune escape from neutralizing antibodies produced by immunizations and increase ACE2 receptor binding affinity. In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). Notably, one high or low dose of Ad26.COV2.S provides more durable immunity than two primary doses of BNT162b2, and the NVX-CoV2373 booster provides the strongest augmentation of immunity, reduction in BA.5 viral replication, and disease. Our data demonstrate the immunogenicity and efficacy of different prime/boost vaccine regimens against BA.5 infection in an immune-competent model and provide new insights regarding COVID-19 vaccine strategies.",

author = "Machado, \{Rafael R.G.\} and Walker, \{Jordyn L.\} and Dionna Scharton and Rafael, \{Grace H.\} and Mitchell, \{Brooke M.\} and Reyna, \{Rachel A.\} and \{de Souza\}, \{William M.\} and Jianying Liu and Walker, \{David H.\} and Plante, \{Jessica A.\} and Plante, \{Kenneth S.\} and Weaver, \{Scott C.\}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41467-023-40033-2",

language = "English",

volume = "14",

number = "1",

}

TY - JOUR

T1 - Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

AU - Machado, Rafael R.G.

AU - Walker, Jordyn L.

AU - Scharton, Dionna

AU - Rafael, Grace H.

AU - Mitchell, Brooke M.

AU - Reyna, Rachel A.

AU - de Souza, William M.

AU - Liu, Jianying

AU - Walker, David H.

AU - Plante, Jessica A.

AU - Plante, Kenneth S.

AU - Weaver, Scott C.

PY - 2023/12

Y1 - 2023/12

N2 - The SARS-CoV-2 Omicron subvariant BA.5 rapidly spread worldwide and replaced BA.1/BA.2 in many countries, becoming globally dominant. BA.5 has unique amino acid substitutions in the spike protein that both mediate immune escape from neutralizing antibodies produced by immunizations and increase ACE2 receptor binding affinity. In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). Notably, one high or low dose of Ad26.COV2.S provides more durable immunity than two primary doses of BNT162b2, and the NVX-CoV2373 booster provides the strongest augmentation of immunity, reduction in BA.5 viral replication, and disease. Our data demonstrate the immunogenicity and efficacy of different prime/boost vaccine regimens against BA.5 infection in an immune-competent model and provide new insights regarding COVID-19 vaccine strategies.

AB - The SARS-CoV-2 Omicron subvariant BA.5 rapidly spread worldwide and replaced BA.1/BA.2 in many countries, becoming globally dominant. BA.5 has unique amino acid substitutions in the spike protein that both mediate immune escape from neutralizing antibodies produced by immunizations and increase ACE2 receptor binding affinity. In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). Notably, one high or low dose of Ad26.COV2.S provides more durable immunity than two primary doses of BNT162b2, and the NVX-CoV2373 booster provides the strongest augmentation of immunity, reduction in BA.5 viral replication, and disease. Our data demonstrate the immunogenicity and efficacy of different prime/boost vaccine regimens against BA.5 infection in an immune-competent model and provide new insights regarding COVID-19 vaccine strategies.

UR - https://www.scopus.com/pages/publications/85165025070

UR - https://www.scopus.com/pages/publications/85165025070#tab=citedBy

U2 - 10.1038/s41467-023-40033-2

DO - 10.1038/s41467-023-40033-2

M3 - Article

C2 - 37460536

AN - SCOPUS:85165025070

SN - 2041-1723

VL - 14

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 4260

ER -

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto